We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Renal Cell Carcinoma
Center of Excellence
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
No comments yet, be the first to start the discussion!
George Yaghmour
Oct 19, 2015
Interesting to share. Votrient is better tolerable with better quality of life than sunitinib according to NEJM 2014 papers. However, reviewing the patient medication especially if he is taking any drug would interact and suppress the liver metabolism by Cytochrome should be considered and 400 mg should be considered. While the patient having HTN and other side effects revealing better efficacy,and side effect management and symptoms control would help. if the symptoms is affecting the daily life activity and grade 3-4 would consider switching to other TKI. In this case restating images to evaluate efficacy in 6-8 weeks interval per the trial protocol. So I would suggest to repeat scan and discuss either to continue with symptoms support and reduce to 400 then increase back slowly or switch to Sutent or other TKI.
Angel Rodriguez
Oct 29, 2015
If there is objective response to pazopanib, lower doses to control toxicity. I've seen response to pazopanib at dose of 200 mg/day.
Alberto Palma
Nov 20, 2015
I believe that under pazopanib doses can reduce the toxicity of this patient, but I fear that this doosagens are not really effective in the treatment of renal tumors.
Trade to Temsorolimus because it was the only drug that showed overall survival gain in such a scenario disease, when the disease can be classified as high risk, or even Interferon and bevacizumab, is also there to Temsirolimus prohibitive toxicity.
George Yaghmour
Nov 30, 2015
Would also might consider of PD1/PDL1, molecular alteration testing if possible and checkpoint inhibitors therapy.
Apr 18, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
Andrew
Fintel
DO
George Yaghmour
Oct 19, 2015
Angel Rodriguez
Oct 29, 2015
Alberto Palma
Nov 20, 2015
George Yaghmour
Nov 30, 2015
Apr 18, 2024
Pending Moderator approval.